Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you consider switching capmatinib to tepotinib or vice versa due to grade 3 hepatotoxicity in a patient with metastatic NSCLC with MET Exon 14 skipping mutation?
Related Questions
Is DLL3 expression necessary for tarlatamab efficacy in small cell lung cancer?
Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?
How do you typically approach adjuvant therapy for a Masaoka stage IVa thymoma post-R0 resection?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
How would you treat patient with a stage IV lung adenocarcinoma, an exon 21 p.H835L mutation, high TMB, and negative PD-L1?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
Would you consider bevacizumab for a patient with SCLC who has asymptomatic brain metastasis progression after CNS radiation while on maintenance immunotherapy?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
